Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884555 | 0.94 | CCNT1 (0.42) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL2214089 | 0.91 | MAPT (0.44) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL2213882 | 0.89 | SMN1; SMN2 (0.45) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL2212035 | 0.85 | SMN1; SMN2 (0.39) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL2212656 | 0.83 | SMN1; SMN2 (0.35) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL2214323 | 0.80 | ALDH1A1 (0.41) | MAPTSMN1; SMN2RAB9ALMNACCNT1 | |
| SCHEMBL2216178 | 0.79 | DHODH (0.43) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL2881754 | 0.79 | MAPT (0.39) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL2213284 | 0.77 | NPC1 (0.38) | MAPTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL2882015 | 0.77 | CYP17A1 (0.47) | MAPTSMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797096-B1 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7745446-B2 | Pyrazolo[1,5-c]pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20070254046-A1 | Novel Pyrazolopyrimidines | ALTANA PHARMA AG (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254046-A1 | Novel Pyrazolopyrimidines | MCL1, RARS2, CDK4 | MAPT 3832/4885SMN1; SMN2 1421/4885NPC1 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.